Orphazyme AS (ORPHA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orphazyme AS (ORPHA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8139
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orphazyme A/S (Orphazyme) formerly Orphazyme ApS, is a biopharmaceutical company that develops heat shock protein based therapies for the treatment of orphan protein-misfolding diseases. Its lead product drug candidate arimoclomol is under clinical development for treating neuromuscular diseases such as sporadic Inclusion Body Myositis (sIBM) and Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases including Niemann-Pick disease Type C (NPC) and Gaucher disease. Orphazyme’s technology is based on heat-shock response generated through the production of heat-shock proteins which protects cells from protein aggregation and misfolding. The company seeks to work in partnerships with other companies for commercialization, licensing and sales opportunities across the US and Europe markets. Orphazyme is headquartered in Copenhagen, Denmark.

Orphazyme AS (ORPHA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orphazyme A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Orphazyme A/S, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Orphazyme Raises USD14.8 Million in Venture Financing 10
Orphazyme Raises USD24 Million in Series B Financing 12
Partnerships 14
Centogene Enters into Agreement with Orphazyme 14
Equity Offering 15
Orphazyme Raises USD107.6 Million in IPO 15
Orphazyme A/S – Key Competitors 16
Orphazyme A/S – Key Employees 17
Orphazyme A/S – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
Apr 17, 2018: Orphazyme announces establishment of US subsidiary in Massachusetts 19
Financial Announcements 20
Aug 28, 2018: Orphazyme reports financial results for the first six months of 2018 20
Mar 15, 2018: Orphazyme announces Annual Report 2017 21
Corporate Communications 22
Nov 16, 2017: Election of new members of the Board of Directors 22
Product News 23
12/14/2017: Orphazyme Assumes Sponsorship of Phase II/III sIBM Trial 23
Product Approvals 24
Jan 19, 2018: Arimoclomol For NPC Receives Rare Pediatric Disease Designation 24
Nov 07, 2017: Orphazyme Receives Orphan Drug Designation To Arimoclomol For Inclusion Body Myositis From The U.S. FDA 25
Clinical Trials 26
Jun 21, 2018: Enrollment of first patient in Phase II clinical trial for Gaucher disease 26
Jun 04, 2018: Orphazyme Presents at 2018 Parseghian Scientific Conference for Niemann-Pick Type C Research 27
Feb 06, 2018: Poster presentation at WORLDSymposium 2018 – arimoclomol as clinical candidate for treatment of Gaucher disease 28
Jan 24, 2018: Publication of manuscript related to Phase II trial results for arimoclomol in patients with SOD1 ALS 29
May 11, 2017: Orphazyme Completes Enrolment Of Patients For Phase 3 Clinical Trial In Niemann-Pick Type C Disease 30
Other Significant Developments 31
Apr 12, 2018: Orphazyme: Resolution passed at the Annual General Meeting 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Orphazyme A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orphazyme A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orphazyme A/S, Deals By Therapy Area, 2012 to YTD 2018 8
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Orphazyme Raises USD14.8 Million in Venture Financing 10
Orphazyme Raises USD24 Million in Series B Financing 12
Centogene Enters into Agreement with Orphazyme 14
Orphazyme Raises USD107.6 Million in IPO 15
Orphazyme A/S, Key Competitors 16
Orphazyme A/S, Key Employees 17
Orphazyme A/S, Subsidiaries 18

List of Figures
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Orphazyme A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Orphazyme AS (ORPHA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Realord Group Holdings Limited:企業の戦略・SWOT・財務情報
    Realord Group Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Realord Group Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Abu Dhabi National Energy Co (TAQA):石油・ガス:M&Aディール及び事業提携情報
    Summary Abu Dhabi National Energy Company (TAQA), a subsidiary of government-owned Abu Dhabi Water and Electricity Authority, is an energy and water company. It undertakes power generation; exploration, development, production and storage of oil and gas; pipelines and gas storage; and water desalina …
  • Protagonist Therapeutics Inc (PTGX):製薬・医療:M&Aディール及び事業提携情報
    Summary Protagonist Therapeutics Inc (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-prote …
  • Vulcan Materials Company:企業の戦略・SWOT・財務分析
    Vulcan Materials Company - Strategy, SWOT and Corporate Finance Report Summary Vulcan Materials Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Orlando Utilities Commission:発電所・企業SWOT分析
    Orlando Utilities Commission - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Companhia Energetica de Minas Gerais – CEMIG:企業の戦略・SWOT・財務分析
    Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report Summary Companhia Energetica de Minas Gerais - CEMIG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operati …
  • Genting Bhd (GENTING):電力:M&Aディール及び事業提携情報
    Summary Genting Bhd (Genting) is an investment holding and management company. The company operates through its subsidiaries in leisure, hospitality, gaming, entertainment, property development and operation, oil and gas, power generation and palm oil plantation sectors. It manages a portfolio of ho …
  • Lexicon Pharmaceuticals Inc (LXRX):企業の財務・戦略的SWOT分析
    Lexicon Pharmaceuticals Inc (LXRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Virtusa Corp (VRTU):企業の財務・戦略的SWOT分析
    Virtusa Corp (VRTU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • EnServe Group Limited:企業のM&A・事業提携・投資動向
    EnServe Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EnServe Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • EKF Diagnostics Holdings Plc (EKF):企業の財務・戦略的SWOT分析
    EKF Diagnostics Holdings Plc (EKF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Taiwan Financial Holding Co Ltd:企業の戦略・SWOT・財務分析
    Taiwan Financial Holding Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Taiwan Financial Holding Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • LSIS Co Ltd (010120):企業の財務・戦略的SWOT分析
    LSIS Co Ltd (010120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Selex Gruppo Commerciale S.p.A.:企業の戦略・SWOT・財務情報
    Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Selex Gruppo Commerciale S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Reply S.p.A. (REY):企業の財務・戦略的SWOT分析
    Reply S.p.A. (REY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • CNOOC Ltd (883)-エネルギー分野:企業M&A・提携分析
    Summary CNOOC Limited (CNOOC) is an upstream oil and gas exploration and production company. It engages in exploration, development, production and sale of crude oil and natural gas. In offshore China, the company engages in oil and natural gas exploration, development and production in Bohai, Weste …
  • Hewlett Packard Enterprise Co (HPE):企業の財務・戦略的SWOT分析
    Hewlett Packard Enterprise Co (HPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dentsply Sirona Inc (XRAY):企業の財務・戦略的SWOT分析
    Dentsply Sirona Inc (XRAY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Dynapac Co., Ltd.:企業の戦略・SWOT・財務情報
    Dynapac Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dynapac Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Vexim SA (ALVXM):企業の財務・戦略的SWOT分析
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆